In vitro and in vivo inhibitory effect of the combination of Wenxia Changfu Formula with cisplatin in non-small cell lung cancer

Chinese Journal of Integrative Medicine

Volumn 17, Issue 12, 2011, Pages 908-916

  Ji, Xu Ming ^a   Ouyang, Bing ^a   Liu, Heng ^a   Liu, Guo Wei ^a   Wu, Zhi Chun ^a   Yu, Hua Yun ^a   Wang, Chun Yan ^a   Wang, Zhong Xia ^a   Wang, Wen Ping ^a  

^a SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cell cycle; Cell cycle related proteins; Chemotherapy; Chinese medicine; Inhibitory effect; Non small cell lung cancer; Wenxia Changfu Formula

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACONITINE; ANTINEOPLASTIC AGENT; CHINESE DRUG; CISPLATIN; CYCLIN D1; CYCLINE; DIMETHYL SULFOXIDE; EMODIN; MESSENGER RNA; PROTEIN P16; RETINOBLASTOMA PROTEIN; RHUBARB EXTRACT; UNCLASSIFIED DRUG; WENXIA CHANGFU FORMULA; HERBACEOUS AGENT; TUMOR PROTEIN; WENXIA CHANGFU;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; SPLEEN; THYMUS; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; DRUG POTENTIATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; DRUG SYNERGISM; DRUGS, CHINESE HERBAL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM PROTEINS; RATS; RATS, WISTAR; RNA, MESSENGER; SPLEEN; THYMUS GLAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859904826     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-011-0934-5     Document Type: Article

References (33)

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Nonsmall cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-594.
2. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008;83:355-367.
3. Charloux A, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 1997;26:14-23.
4. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-1380.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer. N Engl J Med 2002;346:92-98.
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2008;58:71-96.
7. Klastersky J, Sculier JP, Bureau G, Libert P, Ravez P, Vandermoten G, et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 1989;7:1087-1092.
8. Tresure J. Herbal medicine and cancer: an introductory overview. Semin Oncol Nurs 2005;21:177-183.
9. Ji XM, Ouyang B. Effect of medicated serum Wenxia herbs on calcium concentration and mitochondrial membrane potential in Lovo cell. Chin J Tradit Med Sci Technol (Chin) 2006;13:176.
10. Oouyang B, Ji XM. Effects of medicated serum Wenxia herbs on Bcl-2, p53 expression and inducing apoptosis of Lovo cells. J Shandong Univ Tradit Chin Med (Chin) 2006;30:382-383.
11. Ji XM, Ouyang B, Zhang GJ, Li WH, Wang CY, Zhang YQ. Inhibitory effect of Wenxiafang on Lewis lung carcinoma in mice and influences to cell cycle. Chin J Cancer Prev Treat (Chin) 2007;14:339-341.
12. Ji XM, Ouyang Bing, Wang CY. Wenxia Formular restrain the multiplication of the A549 cells and the infection to the expression of PCNA, Rb and cyclin D1. Chin Arch Tradit Chin Med (Chin) 2010;28:721-723.
13. Ouyang B, Ji XM, Wang CY, Zhang YQ. Effects of medicated serum Wenxia Compound Prescription on erB-2, Topo-II expression and cisplatin in A549/DDP cell. J New Chin Med (Chin) 2008;40:101-102.
14. Jin ZJ. The addition in the drug combination. Acta Pharmacol Sin 1980;1:70-76.
15. Poot M, Zhang YZ, Krämer JA, Wells KS, Jones LJ, Hanzel DK, et al. Analysis of mitochondrial morphology and function with novel fixable fluorescent stains. Histochem Cytochem 1996;44:1363-1372.
16. Lau WK, Yeung CW, Lui PW, Cheung LH, Poon NT, Yung KK. Different trends in modulation of NMDARl and NMDAR2B gene expression in cultured cortical and hippocanipal neurons after lead exposure. Brain Res 2002;932:10-24.
17. Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A, et al. Paclitaxelcarboplatin alone or with Bevacizumab in non-small cell lung cancer. N Eng J Med 2006;355:2542-2550.
18. Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: in vitro and in vivo. J Exp Clin Cancer Res 2010;29:87-98.
19. Ji XM, OY B, Li WH. Effect of Wenxia herbs to immune function and restraining on tumor growth. Inf Tradit Chin Med (Chin) 2003;20:48-49.
20. Xia QS, Sun RY, Xiu RJ. Progress of research on molecular mechanism in antitumor effect of emodine. Chin J Integr Tradit West Med (Chin) 2009;29:85-88.
21. Dong LF, Zhang YJ, Liu JS, Song SX, Hou J, Lu ZJ. Anti-tumor effect of monkshood poly-saccharide with adriamycin long circulating temperature sensitive liposome and its mechanism. Chin J Cell Mol Immunol (Chin) 2006;22:458-462.
22. Wu FL, Shi XM, Qian H, Shan FP. The latest development of the studies on antitumor mechanism of Ginseng polysaccharides. Northwest Pharm J (Chin) 2010;25:390-391.
23. Cao W, Li XQ, Hou Y, Fan HT, Zhang XN, Mei QB. Structural analysis and anti-tumor activity in vivo of polysaccharide APS-2a from Angelica sinensis. J Chin Med Mater (Chin) 2008;31:261-266.
24. Marx J. Researchers find new role for cell cycle proteins. Science 1994;263:1093.
25. Udhayakumar G, Jayanthi V, Devaraj N, Devaraj H. Interaction of MUC1 with beta-catenin modulates the Wnt target gene cyclin D1 in H. pylori-induced gastric cancer. Mol Carcinog 2007; 46:807-817.
26. Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998;16:311-320.
27. Gibson SL, Dai CY, Lee HW, DePiho RA, Gee MS, Lee WM, et al. Inhibition of colon tumor progression and angiogenesis by the ink4a/Arf locus. Cancer Res 2003;63:742-746.
28. Grillo M, Bott MJ, Khandke N, McGinnis JP, Miranda M, Meyyappan M, et al. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNAmediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res Treat 2006;95:185-194.
29. Lukas J, Aagaard L, Strauss M, Bartek J. Oncogenic aberrations of p16 INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res 1995;55:4818-4823.
30. Zhao X, Song T, He Z, Tang L, Zhu Y. A novel role of cyclin D1 and p16 in clinical pathology and prognosis of childhood medulloblastoma. Med Oncol 2010;27:985-991.
31. Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 2003;129:199-221.
32. Koundrioukoff S, Jonsson ZO, Hasan S, de Jong RN, van der Vliet PC, Hottiger MO, et al. A direct interaction between proliferating cell nuclear antigen (PCNA) and Cdk2 targets PCNA-interacting proteins for phosphorylation. J Biol Chem 2000;275:22882-22887.
33. Cayrol C, Ducommun B. Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene 1998;17:2437-2444.